Efficacy of lamivudine therapy in elderly patients with chronic hepatitis B infection

Journal of Gastroenterology

Volumn 42, Issue 5, 2007, Pages 395-401

  Kawaoka, Tomokazu ^a   Suzuki, Fumitaka ^a   Akuta, Norio ^a   Suzuki, Yoshiyuki ^a   Arase, Yasuji ^a   Sezaki, Hitomi ^a   Kawamura, Yusuke ^a   Hosaka, Tetsuya ^a   Kobayashi, Masahiro ^a   Ikeda, Kenji ^a   Kumada, Hiromitsu ^a  

^a TORANOMON HOSPITAL   (Japan)

Author keywords

Elderly patients; HBV; Lamivudine; YMDD mutant

Indexed keywords

ADEFOVIR DIPIVOXIL; BILIRUBIN; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; VIRUS DNA; ALANINE AMINOTRANSFERASE; HEPATITIS B ANTIGEN; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BILIRUBIN BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG TOLERABILITY; ELDERLY CARE; FEMALE; FOLLOW UP; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; JAPAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTIVARIATE ANALYSIS; NONHUMAN; PRIORITY JOURNAL; RISK FACTOR; VIRUS LOAD; VIRUS RESISTANCE; AGE; BLOOD; COMPARATIVE STUDY; GENETICS; MIDDLE AGED; TREATMENT OUTCOME;

ADULT; AGE FACTORS; ALANINE TRANSAMINASE; DNA, VIRAL; FEMALE; HEPATITIS B ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; REVERSE TRANSCRIPTASE INHIBITORS; TREATMENT OUTCOME;

EID: 34447548565     PISSN: 09441174     EISSN: 14355922     Source Type: Journal    
DOI: 10.1007/s00535-007-2015-2     Document Type: Article

References (27)

1. M Kane 1995 Global programme for control of hepatitis B infection Vaccine 13 Suppl 1 S47-9 7571830
2. SL Doong CH Tsai RF Schinazi DC Liotta YC Cheng 1991 Inhibition of the replication of hepatitis B virus in vitro by 2,3-dideoxy-3-thiacytidine and related analogues Proc Natl Acad Sci U S A 88 8495-9 1656445 10.1073/ pnas.88.19.8495 1:CAS:528:DyaK3MXms12qurk%3D
3. JL Dienstag RP Perrillo ER Schiff M Bartolomew C Vicary M Rubin 1995 A preliminary trial of lamivudine for chronic hepatitis B infection N Engl J Med 333 1657-61 7477217 10.1056/NEJM199512213332501 1:CAS:528:DyaK28XkvFyqtw%3D%3D
4. F Nevens J Main P Honkoop DL Tyrrell J Barber MT Sullivan 1997 Lamivudine therapy for chronic hepatitis B: A 6-month randomized dose: ranging study Gastroenterology 113 1258-63 9322520 10.1053/ gast.1997.v113.pm9322520 1:CAS:528:DyaK2sXmslOlsbo%3D
5. CL Lai RN Chien NWY Leung TT Chang R Guran DI Tai 1998 Lamivudine therapy for chronic hepatitis B: A 12-month double-blind, placebo-controlled multicenter study N Engl J Med 339 61-8 9654535 10.1056/NEJM199807093390201 1:CAS:528:DyaK1cXkvVSqtbY%3D
6. A Tsubota Y Arase S Saitoh M Kobayashi Y Suzuki F Suzuki 2001 Lamivudine therapy for spontaneously occurring severe acute exacerbation in chronic hepatitis B virus infection: A preliminary study Am J Gastroenterol 96 557-62 11232706 10.1111/j.1572-0241.2001.03559.x 1:CAS:528:DC%2BD3MXisVGhtb8%3D
7. Y Suzuki H Kumada K Ikeda K Chayama Y Arase S Saitoh 1999 Histological changes in liver biopsies after 1 year of lamivudine treatment in patients with chronic hepatitis B infection J Hepatol 30 743-8 10365796 10.1016/S0168-8278(99)80123-8 1:CAS:528:DyaK1MXjtlKntLw%3D
8. Y Suzuki Y Arase K Ikeda S Saitoh A Tsubota F Suzuki 2003 Histological improvements after a 3-year lamivudine therapy in patients with chronic hepatitis B in whom YMDD mutants did not or did develop Intervirology 46 164-70 12867754 10.1159/000071457 1:CAS:528:DC%2BD3sXntFyqsbo%3D
9. H Ooga F Suzuki A Tsubota Y Arase Y Suzuki N Akuta 2004 Efficacy of lamivudine treatment in Japanese patients with hepatitis B virus-related cirrhosis J Gastroenterol 39 1078-84 15580401 10.1007/s00535-004-1450-6 1:CAS:528:DC%2BD2cXhtVCmur3I
10. N Akuta F Suzuki Y Suzuki H Sezaki T Hosaka T Someya 2005 Favorable Efficacy of long-term lamivudine therapy in patients with chronic hepatitis B: An 8-year follow-up study J Med Virol 75 491-8 15714490 10.1002/jmv.20305 1:CAS:528:DC%2BD2MXivFSgtbY%3D
11. N Akuta F Suzuki M Kobayashi A Tsubota Y Suzuki T Hosaka 2003 The influence of hepatitis B virus genotype on the development of lamivudine resistance during long-term treatment J Hepatol 38 315-21 12586297 10.1016/S0168-8278(02)00410-5 1:CAS:528:DC%2BD3sXhtVemtbg%3D
12. N Akuta F Suzuki M Kobayashi M Matsuda J Sato K Takagi 2003 Virological and biochemical relapse according to YMDD motif mutant type during long-term lamivudine monotherapy J Med Virol 71 504-10 14556262 10.1002/ jmv.10519 1:CAS:528:DC%2BD3sXptlCnu7s%3D
13. P Honkoop HG Niesters RA de Man AD Osterhaus SW Schalm 1997 Lamivudine resistance in immunocompetent chronic hepatitis B. Incidence and patterns J Hepatol 26 1393-5 9210628 10.1016/S0168-8278(97)80476-X 1:CAS:528:DyaK2sXksFGksr4%3D
14. K Chayama Y Suzuki M Kobayashi M Kobayashi A Tsubota M Hashimoto 1998 Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild-type after cessation of therapy Hepatology 27 1711-6 9620347 10.1002/hep.510270634 1:CAS:528:DyaK1cXjvVCrs78%3D
15. F Suzuki A Tsubota Y Arase Y Suzuki N Akuta T Hosaka 2003 Efficacy of lamivudine therapy and factors associated with emergence of resistance in chronic hepatitis B virus infection in Japan Intervirology 46 182-9 12867757 10.1159/000071460 1:CAS:528:DC%2BD3sXntFyqsbg%3D
16. M Kobayashi Y Arase K Ikeda A Tsubota Y Suzuki S Saitoh 2002 Clinical characteristics of patients infected with hepatitis B virus genotypes A, B and C J Gastroenterol 37 35-9 11824798 10.1007/s535-002-8130-z
17. S Nafa S Ahmed D Tavan C Pichouc F Berby L Stuyver 2000 Early detection of viral resistance by determination of hepatitis B virus polymerase mutation in patients Hepatology 32 1078-88 11050059 10.1053/ jhep.2000.19619 1:STN:280:DC%2BD3M%2FivFagsQ%3D%3D
18. F Suzuki Y Suzuki A Tsubota N Akuta T Someya M Kobayashi 2002 Mutations of polymerase, precore and core promoter gene in hepatitis B virus during 5-year lamivudine therapy J Hepatol 37 824-30 12445424 10.1016/ S0168-8278(02)00281-7 1:CAS:528:DC%2BD38XoslCjtbo%3D
19. N Akuta A Tsubota F Suzuki Y Suzuki T Hosaka T Someya 2003 Long-term prognosis by lamivudine monotherapy for severe acute exacerbation in chronic hepatitis B infection: Emergence of YMDD mutant and risk of breakthrough hepatitis - an open cohort study J Hepatol 38 91-7 12480565 10.1016/S0168-8278(02)00335-5 1:CAS:528:DC%2BD38XptlSqtLs%3D
20. RP Perrillo ER Schiff E Yoshida A Statler K Hirsch T Wright 2000 Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants Hepatology 32 129-34 10869300 10.1053/jhep.2000.8626 1:CAS:528:DC%2BD3cXltFWgs7c%3D
21. CL Lai M Rosmawati J Lao HV Vlierberghe FH Anderson N Thomas 2003 Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection treated by lamivudine for chronic hepatitis B. infection Gastroenterology 123 1831-8 10.1053/ gast.2002.37058
22. ML Chang RN Chien CT Yeh YF Liaw 2005 Virus and transaminase levels determine the emergence of drug resistance during long-term lamivudine therapy in chronic hepatitis B J Hepatol 43 72-7 15896869 10.1016/ j.jhep.2005.02.021 1:CAS:528:DC%2BD2MXlt1GhsLY%3D
23. WH Adler JE Nagel 1994 Clinical immunology and aging WR Hazzard EL Bierman JP Blass WH Ettinger JB Halter Principles of geriatric medicine and gerontology, 3rd ed McGraw-Hill New York 61-75
24. JM Cook N Gualde L Hessel M Mounier JP Michel F Denis 1987 Alterations in the human immune response to the hepatitis B vaccine among the elderly Cell Immunol 109 89-96 2958144 10.1016/0008-8749(87)90294-2 1:STN:280:BieD3c3js1I%3D
25. EL Marcus R Tur-Kaspa 1997 Viral hepatitis in older adults J Am Geriatr Soc 45 755-63 9180674 1:STN:280:ByiA38vls10%3D
26. T Hosaka F Suzuki Y Suzuki S Saitoh M Kobayashi T Someya 2004 Adefovir dipivoxil for treatment of breakthrough hepatitis caused by lamivudine-resistant mutants of hepatitis B virus Intervirology 47 362-9 15564749 10.1159/000080881 1:CAS:528:DC%2BD2cXhtVagsbfM
27. F Suzuki H Kumada H Nakamura 2006 Changes in viral loads of lamivudine-resistant mutants and evolution of HBV sequences during adefovir dipivoxil therapy J Med Virol 78 1025-34 16789011 10.1002/ jmv.20658 1:CAS:528:DC%2BD28Xnsl2lt7k%3D